Moderna's Transition Year: RSV and CMV Prospects Gain Investor Attention
TL;DR Summary
Moderna's stock jumped 9.5% after the company reported a surprise profit of $217 million in Q4, driven by better-than-expected revenue from international sales of its Spikevax COVID-19 vaccine. The company also benefited from recognizing deferred revenue related to Gavi, the Vaccine Alliance. While risk-averse investors may prefer other stocks, aggressive investors could find Moderna appealing, especially with potential upcoming regulatory approvals for its RSV and seasonal flu vaccines.
- Why Moderna Stock Is Jumping Today Yahoo Finance
- Moderna Is Pivoting From Covid—the Results Are on Their Way The Wall Street Journal
- Moderna stock jumps after company posts surprise quarterly profit even as Covid vaccine sales plunge CNBC
- Investors hone in on Moderna's RSV, CMV prospects after 'transition' year Fierce Biotech
- As COVID vaccine sales plummet, Moderna gains ground on Pfizer FiercePharma
Reading Insights
Total Reads
0
Unique Readers
11
Time Saved
2 min
vs 3 min read
Condensed
84%
431 → 68 words
Want the full story? Read the original article
Read on Yahoo Finance